Patents by Inventor Paul YOON
Paul YOON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11915139Abstract: Methods, systems, and apparatus for updating machine learning models to improve locality are described. In one aspect, a method includes receiving data of a machine learning model. The data represents operations of the machine learning model and data dependencies between the operations. Data specifying characteristics of a memory hierarchy for a machine learning processor on which the machine learning model is going to be deployed is received. The memory hierarchy includes multiple memories at multiple memory levels for storing machine learning data used by the machine learning processor when performing machine learning computations using the machine learning model. An updated machine learning model is generated by modifying the operations and control dependencies of the machine learning model to account for the characteristics of the memory hierarchy. Machine learning computations are performed using the updated machine learning model.Type: GrantFiled: February 15, 2022Date of Patent: February 27, 2024Assignee: Google LLCInventors: Doe Hyun Yoon, Nishant Patil, Norman Paul Jouppi
-
Patent number: 11786595Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: GrantFiled: April 12, 2021Date of Patent: October 17, 2023Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Patent number: 11577092Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.Type: GrantFiled: August 1, 2017Date of Patent: February 14, 2023Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne Beyer, Mark Oldham, Justus Adamson, Paul Yoon
-
Publication number: 20220226666Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.Type: ApplicationFiled: March 21, 2022Publication date: July 21, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, JR., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Patent number: 11305131Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: GrantFiled: August 29, 2019Date of Patent: April 19, 2022Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark DeWhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Publication number: 20220062419Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: ApplicationFiled: April 12, 2021Publication date: March 3, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. Bourke, JR., Zakaryae FATHI, Wayne F. BEYER, JR.
-
Patent number: 11207409Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: GrantFiled: May 30, 2018Date of Patent: December 28, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Mark Dewhirst, Neil Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada, Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder
-
Patent number: 11135294Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: GrantFiled: October 26, 2016Date of Patent: October 5, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Patent number: 10940329Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.Type: GrantFiled: November 21, 2017Date of Patent: March 9, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer
-
Publication number: 20200009398Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: ApplicationFiled: August 29, 2019Publication date: January 9, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Frederic A. BOURKE, JR., Harold WALDER, Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
-
Patent number: 10441810Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: GrantFiled: February 16, 2017Date of Patent: October 15, 2019Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Publication number: 20190184190Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.Type: ApplicationFiled: August 1, 2017Publication date: June 20, 2019Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, Zakaryae FATHI, Wayne BEYER, Mark OLDHAM, Justus ADAMSON, Paul YOON
-
Publication number: 20180344850Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: ApplicationFiled: May 30, 2018Publication date: December 6, 2018Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. BOURKE, JR., Mark DEWHIRST, Neil SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA, Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER
-
Publication number: 20180311355Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: ApplicationFiled: October 26, 2016Publication date: November 1, 2018Inventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. BOURKE, Zakaryae FATHI, Wayne F. BEYER
-
Publication number: 20180154178Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.Type: ApplicationFiled: November 21, 2017Publication date: June 7, 2018Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Paul Yoon, Harold Walder, Frederic A. Bourke, JR., Zakaryae Fathi, Wayne F. Beyer
-
Publication number: 20170157418Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: ApplicationFiled: February 16, 2017Publication date: June 8, 2017Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER, Frederic A. BOURKE, JR., Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA